Self-measurement of blood glucose in patients with type 2 diabetes: A health economic assessment

Journal of Diabetes Science and Technology

Volumn 1, Issue 5, 2007, Pages 676-684

  Weber, Christian ^a   Neeser, Kurt ^a   Schneider, Berthold ^b   Lodwig, Volker ^a  

^a Institute for Medical Informatics and Biostatistics   (Switzerland)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

CEA; Cost effectiveness; Costs; Diabetes mellitus type 2; Self measurement of blood glucose; SMBG

Indexed keywords

EID: 44249095150     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100511     Document Type: Article

References (44)

1. Ipp E, Aquino RL, Christenson P. Point: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: the sanguine approach. Diabetes Care. 2005 Jun; 28(6):1528-30.
2. Davidson MB. Counterpoint: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money. Diabetes Care. 2005 Jun; 28(6):1531-3.
3. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care. 2005 Jun; 28(6):1510-7.
4. Sarol JN, Nicodemus NA, Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin. 2005 Feb; 21(2):173-83.
5. Jansen J P. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006 Apr; 22(4):671-81.
6. Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, Kolb H, Scherbaum WA. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia. 2006 Feb; 49(2):271-8.
7. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB, Jr., Ferrara A, Liu J, Selby JV. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001 Jul; 111(1):1-9.
8. Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, Selby JV. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care. 2006 Aug; 29(8):1757-63.
9. Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care. 2006 Aug; 29(8):1764-70.
10. International Diabetes Federation. Diabetes atlas. 2nd ed. Paris, France; 2003.
11. Hauner H. [Epidemiology and costs of diabetes mellitus in Germany]. Dtsch Med Wochenschr. 2005 Jul. 8;130 Suppl 2:S64-5.
12. Weber C, Neeser K, Wenzel H, Schneider B. [Costs of diabetes mellitus type 2 and self measurement of blood glucose in Germany]. Versicherungsmedizin. 2006 Sep. 1;58(3):133-7.
13. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003 Mar; 25(3):1017-38.
14. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res. 2003 Mar. 21;3(1):7.
15. Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004;22(3):149-64.
16. Neeser K, Erny-Albrecht K, Weber C. Cost-effectiveness of self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin. Diabetes Care. 2006 Feb; 29(2):480.
17. Palmer AJ, Dinneen S, Gavin JR, Gray A, Herman WH, Karter AJ. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin. 2006 May; 22(5):861-72.
18. Weber C, Neeser K, Wenzel H, Schneider B. Cost of type 2 diabetes in Germany over 8 years (the ROSSO study No. 2). J Med Econ. 2006;9:45-53.
19. Weber C, Neeser K. Using individualized predictive disease modeling to identify patients with the potential to benefit from a disease management program for diabetes mellitus. Dis Manag. 2006 Aug; 9(4):242-56.
20. Pharmacoeconomic guidelines around the world. International Society for Pharmacoeconmics and Outcome Research (ISPOR) 2006. Available from: http://www.ispor.org/PEguidelines/countrydet. asp?c=9&t=1
21. Meyer G, Muhlhauser I. Comment to: Martin S, Schneider B, Heinemann L et al (2006) Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49:271-278.
22. Diabetologia. 2006 Jul; 49(7):1702-173.
23. Martin S, Heinemann L, Scherbaum WA, Kolb H. Reply to comment on: Martin S, Schneider B, Heinemann L et al (2006) Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 49:271-278.
24. Diabetologia. 2006;49(7):1704-5.
25. Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health. 2001 Sep; 4(5):348-61.
26. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003 Jan-Feb; 6(1):9-17.
27. Weinstein MC. A Report of the ISPOR Health Science Committee-Task Force on Good Research Practices-Modeling Studies. ISPOR 2005.
28. Sulpher M, Drummond M. Analysis Sans Frontières: Can we ever make economic evaluations generalisable across jurisdictions? Pharmacoeconomics. 2006 Jan 1;24(11):1087-99.
29. Manca A, Willan A. "Lost in translation": Accounting for between-country differences in the analysis of multinational costeffectiveness data. Pharmacoeconomics. 2006 Jan 1;24(11):1101-19.
30. Hinzpeter B, Klever-Deichert G, Wendland G, Lauterbach KW. [Coronary disease and social security. A simulation model on cost analysis]. Herz. 2000 Aug; 25(5):515-25.
31. Szucs TD, Schwenkglenks M, Paschen B, Follath F. [Costeffectiveness of bisoprolol in treatment of heart failure in Germany. An analysis based on the CIBIS-II study]. Med Klin (Munich). 2000 Dec. 15;95(12):663-71.
32. Banz K, Dinkel R, Hanefeld M, Schwanebeck U. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus. A decisionanalytical approach. Pharmacoeconomics. 1998 Apr; 13(4):449-59.
33. Laaser U, Breckenkamp J, Niermann U. Cost-effectiveness-analysis of medical interventions in patients with stroke in Germany under special consideration of "stroke units". Gesundh ökon Qual Manag. 1999;4:176-83.
34. Szucs TD, Guggenberger G, Berger K, Marz W, Schafer JR. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]. Herz. 1998 Aug; 23(5):319-29.
35. Holler D, Claes C, Der Schulenburg JM. Treatment costs and quality of life of patients with peripheral arterial occlusive disease - the German perspective. Vasa. 2004 Aug; 33(3):145-53.
36. Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care. 2002 Feb; 11(2):70-4.
37. Dahmen HG. [Diabetic foot syndrome and its risks: amputation, handicap, high-cost sequelae]. Gesundheitswesen. 1997 Oct; 59(10):566-8.
38. Szucs TD, Smala AM, Fischer T. [Costs of intensive insulin therapy in type 1 diabetes mellitus. Experiences from the DCCT study]. Fortschr Med. 1998 Nov. 10;116(31):34-8.
39. Gozzoli V, Palmer AJ, Brandt A, Weiss C, Piehlmeier W, Landgraf R, Renner R. [Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients]. Dtsch Med Wochenschr. 2000 Sep. 29;125(39):1154-9.
40. Gesundheitsbericht für Deutschland 1998. In: Statistisches Bundesamt, editor. Wiesbaden: Metzler-Poeschel (Stuttgart); 1998. p. 341-5.
41. Salize HJ, Stamm K, Schubert M, Bergmann F, Harter M, Berger M, Gaebel W, Schneider F. [Cost of care for depressive disorders in primary and specialized care in Germany]. Psychiatr Prax. 2004 Apr; 31(3):147-56.
42. Rathmann W, Haastert B, Giani G. [Drug prescriptions and costs in diabetic polyneuropathy]. Dtsch Med Wochenschr. 1999 Jun. 4;124(22):681-6.
43. Köhler A, Hess R. Kölner Kommentar zum EBM. 2nd ed. Köln: Deutscher Ärzte-Verlag; 2002.
44. Arzneiverordnungsreport 2004. Berlin: Springer; 2004.